Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity

Background: The prevalence of HIV-associated neurocognitive disorders is increasing as HIV-infected individuals are living longer. The clinical manifestations of the syndrome also continue to evolve under the influence of antiretroviral drugs and comorbidities such as drugs of abuse. However, there are no surrogate markers for the disease, either to identify it de novo or to track its progression, and there is no proven treatment with the exception of antiretroviral drugs. Methods: Levels of nitric oxide, nitrate, and 3-nitrotyrosine (3-NT)–modified proteins were measured in the CSF of 46 patients with HIV infection stratified according to their neurocognitive status and history of IV drug use (IVD). The 3-NT–modified proteins were isolated and identified by tandem mass spectrometry, and the functional consequence of 3-NT modification of l-prostaglandin D synthase (l-PGDS), the most abundant protein, was determined. Results: 3-NT–modified proteins were significantly elevated in patients with HIV infection who had progressive neurocognitive decline over the next 6 months and in patients with a history of IVD. Thirteen different proteins with 3-NT modification were identified in the CSF of these patients. l-PGDS was the most abundant. 3-NT modification of this protein resulted in loss of its enzymatic activity. Conclusions: There is increased nitrosative stress in CSF of HIV-infected patients with active dementia and in patients with a history of IV drug use, measurement of which may serve as a surrogate marker for these patients. Nitrosative stress may also have important functional consequences and may impact the pathogenesis of HIV-associated neurocognitive disorders.

[1]  A. Nath,et al.  Neurologic complications: Challenges to the diagnosis and management of HIV dementia , 2006 .

[2]  Caroline Anderson,et al.  Oxidative stress and therapeutic approaches in HIV dementia. , 2006, Antioxidants & redox signaling.

[3]  M. Mattson,et al.  Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: Protection by diosgenin and l-deprenyl , 2006, Neurobiology of Disease.

[4]  I. Singh,et al.  Pharmacological strategies for the regulation of inducible nitric oxide synthase: Neurodegenerative versus neuroprotective mechanisms , 2006, Neurochemistry International.

[5]  A. Nath,et al.  Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. , 2006, Neurotoxicology.

[6]  A. Nath,et al.  Estrogen attenuates gp120‐ and tat1–72‐induced oxidative stress and prevents loss of dopamine transporter function , 2006, Synapse.

[7]  Linda Chang,et al.  Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. , 2005, The American journal of psychiatry.

[8]  T. Hand,et al.  Prostaglandin D2 mediates neuronal protection via the DP1 receptor , 2005, Journal of neurochemistry.

[9]  M. Hersberger,et al.  CCTTT‐repeat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesis , 2004, Clinical and experimental immunology.

[10]  D. Price,et al.  Stabilization of α-Synuclein Protein with Aging and Familial Parkinson's Disease-Linked A53T Mutation , 2004, The Journal of Neuroscience.

[11]  P. Singhal,et al.  Morphine modulates HIV-1 gp160-induced murine macrophage and human monocyte apoptosis by disparate ways , 2004, Journal of Neuroimmunology.

[12]  M. Mattson,et al.  Perturbation of sphingolipid metabolism and ceramide production in HIV‐dementia , 2004, Annals of neurology.

[13]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[14]  S. Fujimoto,et al.  Subject Index Vol. 59, 2003 , 2003, Hormone Research in Paediatrics.

[15]  R. Kuljiš,et al.  Increased density of neurons containing NADPH diaphorase and nitric oxide synthase in the cerebral cortex of patients with HIV-1 infection and drug abuse. , 2003, Journal of neuro-AIDS.

[16]  D. Butterfield,et al.  Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants , 2003, Neurology.

[17]  K. Pahan,et al.  Human Immunodeficiency Virus Type 1 (HIV-1) Tat Induces Nitric-oxide Synthase in Human Astroglia* , 2002, The Journal of Biological Chemistry.

[18]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[19]  Y. Urade,et al.  Perineuronal Oligodendrocytes Protect against Neuronal Apoptosis through the Production of Lipocalin-Type Prostaglandin D Synthase in a Genetic Demyelinating Model , 2002, The Journal of Neuroscience.

[20]  M. Fresno,et al.  Tumor necrosis factor-alpha and nitric oxide in vertically HIV-1-infected children: implications for pathogenesis. , 2001, European cytokine network.

[21]  W. Slikker,et al.  Methamphetamine‐Induced Dopaminergic Neurotoxicity: Role of Peroxynitrite and Neuroprotective Role of Antioxidants and Peroxynitrite Decomposition Catalysts , 2001, Annals of the New York Academy of Sciences.

[22]  A. Bansal,et al.  Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum , 2001, Neuroscience Letters.

[23]  Sunhee C. Lee,et al.  Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis , 2001, Journal of Neuroimmunology.

[24]  M. Mattson,et al.  Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine , 2001, BMC Neuroscience.

[25]  J. Trojanowski,et al.  Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.

[26]  Y. Urade,et al.  Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. , 2000, Biochimica et biophysica acta.

[27]  D. Dormont,et al.  Nitric Oxide Synthesis Enhances Human Immunodeficiency Virus Replication in Primary Human Macrophages , 2000, Journal of Virology.

[28]  Syed F. Ali,et al.  Comparison between the Role of the Neuronal and Inducible Nitric Oxide Synthase in Methamphetamine‐induced Neurotoxicity and Sensitization , 2000, Annals of the New York Academy of Sciences.

[29]  S. Senok,et al.  Methamphetamine‐induced Oxidative Stress in Cultured Mouse Astrocytes , 2000, Annals of the New York Academy of Sciences.

[30]  G. Levi,et al.  Human immunodeficiency virus type 1 Tat protein stimulates inducible nitric oxide synthase expression and nitric oxide production in microglial cultures. , 1999, Journal of neuropathology and experimental neurology.

[31]  T. Kemper,et al.  Human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: Pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex , 1999, Annals of neurology.

[32]  H. Toh,et al.  Binding of biliverdin, bilirubin, and thyroid hormones to lipocalin-type prostaglandin D synthase. , 1999, Biochemistry.

[33]  E. Murray,et al.  Increased expression of nitric oxide synthase and dendritic injury in simian immunodeficiency virus encephalitis. , 1999, Journal of human virology.

[34]  S. Lipton,et al.  The contribution of various NOS gene products to HIV-1 coat protein (gp120)-mediated retinal ganglion cell injury. , 1999, Investigative ophthalmology & visual science.

[35]  D. Troost,et al.  Nitric oxide synthase expression and apoptotic cell death in brains of AIDS and AIDS dementia patients. , 1999, AIDS.

[36]  J. McArthur,et al.  Rate and Severity of HIV-Associated Dementia (HAD): Correlations with Gp41 and iNOS , 1999, Molecular medicine.

[37]  Y. Urade,et al.  Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Y. Urade,et al.  Prostaglandin D2 and sleep regulation. , 1999, Biochimica et biophysica acta.

[39]  T. Dawson,et al.  Mechanisms and Structural Determinants of HIV-1 Coat Protein, gp41-Induced Neurotoxicity , 1999, The Journal of Neuroscience.

[40]  M. Mattson,et al.  HIV-1 Protein Tat Induces Apoptosis of Hippocampal Neurons by a Mechanism Involving Caspase Activation, Calcium Overload, and Oxidative Stress , 1998, Experimental Neurology.

[41]  P. Simmonds,et al.  HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. , 1998, Brain : a journal of neurology.

[42]  B. Yamamoto,et al.  The effects of methamphetamine on the production of free radicals and oxidative stress. , 1998, The Journal of pharmacology and experimental therapeutics.

[43]  C P Das,et al.  Neurological complications of HIV infection. , 1998, Neurology India.

[44]  W. Sheng,et al.  Immunomodulatory role of opioids in the central nervous system. , 1998, Archivum immunologiae et therapiae experimentalis.

[45]  P. Lantos,et al.  HIV‐associated brain pathology in the United Kingdom: an epidemiological study , 1997, AIDS.

[46]  Y. Urade,et al.  Lipocalin-type Prostaglandin D Synthase (β-Trace) Is a Newly Recognized Type of Retinoid Transporter* , 1997, The Journal of Biological Chemistry.

[47]  Justin C. McArthur,et al.  Immunologic NO Synthase: Elevation in Severe AIDS Dementia and Induction by HIV-1 gp41 , 1996, Science.

[48]  J. Egberts,et al.  Urine samples before dinner are preferable when studying changes in endogenous nitrate production under uncontrolled dietary conditions. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[49]  T. Clark,et al.  Investigation of the Uncatalyzed Hydration of CO2 and First Approximations to the Active Site of Carbonic Anhydrase - A Combined Ab initio and DFT Study - , 1996 .

[50]  G. Nuovo,et al.  AIDS Dementia Is Associated with Massive, Activated HIV-1 Infection and Concomitant Expression of Several Cytokines , 1996, Molecular medicine.

[51]  S. Wesselingh,et al.  Elevated central nervous system prostaglandins in human immunodeficiency virus—associated dementia , 1994, Annals of neurology.

[52]  U. Testa,et al.  gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte‐derived macrophages , 1994, Journal of leukocyte biology.

[53]  J. R. Lancaster,et al.  Nitric oxide--a new endogenous immunomodulator. , 1993, Transplantation.

[54]  D. Vlahov,et al.  HIV‐1 infection and nervous system abnormalities among a cohort of intravenous drug users , 1991, Neurology.

[55]  M. Ebadi,et al.  Reactive Macrophages Increase Oxidative Stress and Alpha-Synuclein Nitration During Death of Dopaminergic Neuronal Cells in Co-Culture: Relevance to Parkinson’s Disease , 2005, Neurochemical Research.

[56]  Richard Graham Knowles,et al.  Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat. , 2004, Neuroscience letters.

[57]  K. Kiyomiya,et al.  Involvement of arachidonic acid metabolites in acute inflammation: detection of 6-keto-PGF1 alpha, thromboxane B2 and PGD2 in rat pleurisy induced by phorbol myristate acetate. , 1985, Japanese journal of pharmacology.